A Cannabinoid Hypothesis of Schizophrenia: How Cannabis May Trigger Psychosis

A proposed "cannabinoid hypothesis" of schizophrenia describes multiple pathways through which THC may trigger psychosis, paralleling existing dopamine, serotonin, and glutamate hypotheses.

Little, Rachel et al.·Innovations in clinical neuroscience·2022·Moderate EvidenceNarrative Review
RTHC-04013Narrative ReviewModerate Evidence2022RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
Narrative Review
Evidence
Moderate Evidence
Sample
Not reported

What This Study Found

The review describes several putative pathways from cannabis to psychosis, integrating evidence about the endocannabinoid system, THC's effects on dopamine and glutamate signaling, and the connection between cannabis use and first-episode psychosis.

Key Numbers

Hypothesis parallels existing dopamine, serotonin, and glutamate hypotheses of schizophrenia

How They Did This

Narrative review synthesizing evidence about the endocannabinoid system, THC's neurochemical effects, and epidemiological links between cannabis and psychosis to propose a unified cannabinoid hypothesis.

Why This Research Matters

Understanding the specific biological pathways through which cannabis may trigger psychosis could enable targeted prevention strategies for susceptible individuals.

The Bigger Picture

Just as stimulant-induced psychosis led to the dopamine hypothesis and psychedelic-induced states led to the serotonin hypothesis, cannabis-induced psychosis may reveal a distinct endocannabinoid pathway to schizophrenia.

What This Study Doesn't Tell Us

Narrative review proposing a hypothesis rather than testing one. Pathways described are "putative" and not fully established.

Questions This Raises

  • ?Can genetic variation in the endocannabinoid system identify who is most vulnerable to cannabis-induced psychosis?
  • ?Would targeted interventions based on these pathways prevent schizophrenia in at-risk cannabis users?

Trust & Context

Key Stat:
Multiple putative pathways from cannabis to psychosis identified
Evidence Grade:
Narrative review proposing a hypothesis based on existing evidence rather than presenting new data.
Study Age:
Published in 2022
Original Title:
A Cannabinoid Hypothesis of Schizophrenia: Pathways to Psychosis.
Published In:
Innovations in clinical neuroscience, 19(7-9), 38-43 (2022)
Database ID:
RTHC-04013

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / ObservationalSnapshot without intervening
This study
Case Report / Animal Study

Summarizes existing research without a strict systematic method.

What do these levels mean? →

Frequently Asked Questions

What is the cannabinoid hypothesis of schizophrenia?

It proposes that THC can trigger psychosis through multiple pathways involving the endocannabinoid system, similar to how other drug-induced psychotic states led to the dopamine and serotonin hypotheses of schizophrenia.

Does cannabis cause schizophrenia?

The review describes biological pathways through which cannabis could trigger psychosis in susceptible individuals, but having pathways does not mean everyone who uses cannabis will develop schizophrenia. Susceptibility likely involves genetic and environmental factors.

Read More on RethinkTHC

Cite This Study

RTHC-04013·https://rethinkthc.com/research/RTHC-04013

APA

Little, Rachel; D'Mello, Dale. (2022). A Cannabinoid Hypothesis of Schizophrenia: Pathways to Psychosis.. Innovations in clinical neuroscience, 19(7-9), 38-43.

MLA

Little, Rachel, et al. "A Cannabinoid Hypothesis of Schizophrenia: Pathways to Psychosis.." Innovations in clinical neuroscience, 2022.

RethinkTHC

RethinkTHC Research Database. "A Cannabinoid Hypothesis of Schizophrenia: Pathways to Psych..." RTHC-04013. Retrieved from https://rethinkthc.com/research/little-2022-a-cannabinoid-hypothesis-of

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.